Letrozole

CAS 112809-51-5 14 current records 12 historicalSmall Molecule

Who holds supplier records for Letrozole? 14 organisations hold a current record for Letrozole: an active US FDA Type II Drug Master File or a CEP. A further 12 organisations have only historical (inactive) DMF filings. 12 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (8), Netherlands (2), China (2) and Taiwan (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Letrozole: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/letrozole

Reading the evidence

  • 14 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    8 of the 13 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 10 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (14)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Letrozole. Country is the organisation's recorded country, not necessarily the manufacturing site.

India8Netherlands2China2Taiwan1Country not recorded for 1
Need Letrozole sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (12)

Certificates of Suitability on the EDQM register for Letrozole, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 20 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HETERO LABS LIMITED HyderabadIN
CEP 2012-145 - Rev 04
Letrozole, Form-III
Oct 2026—
WANYANG HENGSHUI PHARMACEUTICAL CO. LTD HengshuiCN
CEP 2026-058 - Rev 00
Letrozole, Micronised
Aug 2026—
NOVARTIS PHARMA AG BaselCH
CEP 2019-149 - Rev 01
Letrozole
Apr 2026Inspected Dec 2025
Switzerland
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2009-147 - Rev 02
Letrozole
Mar 2026—
TAPI NL B.V. AmsterdamNL
CEP 2022-209 - Rev 02
Letrozole
Sept 2025—
JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. LianyungangCN
CEP 2024-379 - Rev 00
Letrozole, Process II
Dec 2024—
SYNTHON B.V. NijmegenNL
CEP 2010-269 - Rev 02
Letrozole, Micronised
Nov 2024Inspected May 2024
Netherlands
SCINOPHARM TAIWAN LTD. Shan-HuaTW
CEP 2008-127 - Rev 03
Letrozole
Sept 2024—
SYNTHIMED LABS PRIVATE LIMITED DerabassiIN
CEP 2009-105 - Rev 05
Letrozole
Aug 2024Inspected Aug 2026
Slovenia
SHILPA PHARMA LIFESCIENCES LIMITED RaichurIN
R1-CEP 2013-321 - Rev 01
Letrozole
Jul 2022—
CIPLA LIMITED MumbaiIN
R1-CEP 2010-300 - Rev 00
Letrozole
Jul 2019—
NATCO PHARMA LIMITED HyderabadIN
R1-CEP 2007-150 - Rev 03
Letrozole
Feb 2017—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (12)

Organisations whose Type II DMFs for Letrozole are no longer active. These show a past filing, not current supply.

Show all 12 historical records
  • MAC CHEM PRODUCTS INDIA PVT LTD
    Inactive DMF 26550 · filed Sept 2012
  • Sichuan Xieli Pharmaceutical Co Ltd
    China · Inactive DMF 26252 · filed Jul 2012
  • Apotex Pharmachem India Pvt. Ltd.
    India · Inactive DMF 25069 · filed Jun 2011
  • MYLAN LABORATORIES LTD
    Inactive DMF 23411 · filed Dec 2009
  • India · Inactive DMF 22239 · filed Dec 2008
  • India · Inactive DMF 21462 · filed Mar 2008
  • India · Inactive DMF 21191 · filed Jan 2008
  • TAI HENG INDUSTRY CO LTD
    Inactive DMF 20761 · filed Jul 2007
  • China · Inactive DMF 20356 · filed Mar 2007
  • SANMAR SPECIALITY CHEMICALS LTD
    Inactive DMF 20020 · filed Dec 2006
  • Italy · Inactive DMF 19622 · filed Jul 2006
  • ALCAMI WISCONSIN CORP
    Inactive DMF 19170 · filed Feb 2006

Overview

Letrozole is an oral non-steroidal aromatase inhibitor used in the treatment of hormonally-responsive breast cancer after surgery. It lowers estrogen levels in postmenopausal women, slowing the growth of certain types of breast tumors that are estrogen-dependent.

Chemical identity

IUPAC name
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
Canonical SMILES
C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
InChIKey
HPJKCIUCZWXJDR-UHFFFAOYSA-N
Synonyms
Femara API, letrozole, Femara, Letrozol, CGS 20267, CGS-20267, CGS20267, CHEBI:6413, NSC719345, letrozolum, Letrozole Tablets, RefChem:55460

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Aromatase Inhibitor
Mechanism of action
Aromatase Inhibitors

Therapeutic areas

Oncology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Letrozole?

14 organisations hold an active US FDA Type II Drug Master File or a CEP for Letrozole: Natco Pharma (India), TAPI NL BV (Netherlands), Cipla Limited (India), Hetero Labs Limited (India), SCINOPHARM TAIWAN LTD (Taiwan), SHILPA PHARMA LIFESCIENCES LTD (India), Sun Pharmaceutical Industries Limited (India) and SYNTHIMED LABS PRIVATE LIMITED (India), and 6 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Letrozole Drug Master Files are active?

Natco Pharma (DMF 22812, 18388), TAPI NL BV (DMF 20566, 21182), Cipla Limited (DMF 20175), Hetero Labs Limited (DMF 24886), SCINOPHARM TAIWAN LTD (DMF 19139), SHILPA PHARMA LIFESCIENCES LTD (DMF 27489), Sun Pharmaceutical Industries Limited (DMF 22632) and SYNTHIMED LABS PRIVATE LIMITED (DMF 22093) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Letrozole records mean?

12 organisations have only inactive Type II DMFs for Letrozole. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Letrozole have a European Certificate of Suitability?

Yes. 12 organisations hold a valid CEP for Letrozole on the EDQM register, including HETERO LABS LIMITED Hyderabad (IN), WANYANG HENGSHUI PHARMACEUTICAL CO. LTD Hengshui (CN), NOVARTIS PHARMA AG Basel (CH), SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), TAPI NL B.V. Amsterdam (NL) and JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Lianyungang (CN) and 6 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Letrozole supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Letrozole?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.